Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: An open parallel long-term study

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 17, Issue 2, 2004, Pages 84-89

  Lepore, Giuseppe ^a   Dodesini, A R ^a   Nosari, I ^a   Trevisan, R ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

CSII; Glargine; MDI therapy; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; AGE; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MALE; METABOLIC REGULATION; PARALLEL DESIGN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 2942560655     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986, 1993.
2. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 23 (Suppl. 1): S32-S42, 2000.
3. Lepore G., Bruttomesso D., Nosari I., Tiengo A., Trevisan R.: Glycaemic control and microvascular complications in a large cohort of Italian Type 1 diabetic out-patients. Diab. Nutr. Metab. 15: 232-239, 2002.
4. Pickup J., Mattock M., Kerry S.: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Br. Med. J. 324: 705-710, 2002.
5. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., Cordoni C., Costa E., Brunetti P., Bolli G.B.: Pharmacokinetics and pharmacodymanics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49: 2142-2148, 2000.
6. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., Wilson C.A.: Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23: 639-643, 2000.
7. Lepore G., Dodesini A.R., Nosari I., Trevisan R.: Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 26: 1321-1322, 2003.
8. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., Taylor WF.: Mean amplitude of glycaemic excursions, a measure of diabetic instability. Diabetes 19: 644-655, 1970.
9. Mathur R., Harmel A.L.P.: A comparison of continuous subcutaneous insulin infusion (CSII) therapy versus multiple daily injection (MDI) therapy with premeal rapid acting insulin and glargine insulin in patients with type 1 diabetes. Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association, June 13-17, 2003, New Orleans (Abstract 1900-PO).
10. Torlone E., Pampanelli S., Porcellati F.: Short-term comparison between glargine as basal insulin and CSII in CSII-treated type 1 diabetic patients switching to MDI: the pump holiday study. Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association, June 13-17, 2003, New Orleans (Abstract LB-13).
11. Bode B., Hirsch I., Hu P., Santiago O.: Type 1 diabetes patients can temporarily switch from continuous subcutaneous insulin infusion with insulin aspart to basal bolus therapy with insulin aspart and insulin glargine. Diabetologia 46 (Suppl. 213): A270, 2003 (Abstract).
12. Boland E., Weinzimer S., Ahern J.A., Steffen A., Tamborlane W.: Randomized, prospective trial of CSII with glargine in children: a preliminary report. Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association, June 13-17, 2003, New Orleans (Abstract 192-OR).
13. Bode B.W., Sabbah H.T., Gross T.M., Fredrickson L.P., Davidson P.C.: Diabetes management in new millennium using insulin pump therapy. Diabetes Metab. Res. Rev. 18 (Suppl. 1): S14-S20, 2002.
14. Binder C., Lauritzen T., Faber O., Pramming S.: Insulin pharmacokinetics. Diabetes Care 7: 188-199, 1984.
15. Marcus A.O., Fernandez M.P.: Insulin pump therapy: acceptable alternative to injection therapy. Postgrad. Med. 99: 125-143, 1996.
16. Bode B.W., Steed R.D., Davidson P.C.: Reduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19: 324-327, 1996.
17. Boland E.A., Grey M., Osterle A., Fredrickson L., Tamborlane W.: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycaemia, improve metabolic control and enhance coping in adolescents with type 1 diabetes. Diabetes Care 22: 1799-1784, 1999.
18. DCCT Research Group: Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 11: 567-573, 1988.
19. Bruttomesso D., Pianta A., Crazzolara D., Scaldaferri E., Lora L., Guarneri G., Mongillo A., Gennaro R., Miola M., Moretti M., Confortin L., Beltramello G.P., Pais M., Baritussio A., Casiglia E., Tiengo A.: Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet. Med. 19: 628-634, 2002.
20. Orchard T.J., Chang Y.F., Ferrell R.E., Petro N., Ellis D.E.: Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int. 62: 963-970, 2002